Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease

Francesca Mancini, Cristina Tassorelli, Emilia Martignoni, Arrigo Moglia, Giuseppe Nappi, Silvano Cristina, Claudio Pacchetti

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Objectives: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out to demonstrate the short- and long-term efficacy of quetiapine, an antipsychotic drug, in controlling hallucinations and delusions in parkinsonian patients without worsening their motor function. Since current guidelines recommend that dopaminergic drugs be decreased or even withdrawn altogether upon the appearance of MDs, we also sought to establish whether quetiapine enables a modification of this common course of action, and hence improve the management of pre-existing motor complications in affected subjects. Method: Thirty-five PD patients with disabling MDs were enrolled in this open-label study. Motor function, MDs and cognitive state were evaluated before starting quetiapine therapy and after 1, 3, and 12 months of treatment. Results: MDs significantly improved after 1, 3, and 12 months of quetiapine treatment. At the end of the study the mean daily dose of quetiapine (185 mg) did not produce significant changes in motor or cognitive function. Isolated hallucinations responded to low doses of quetiapine (110 mg daily), while delusions needed 265 mg daily. After 12 months, global dopaminergic therapy was reduced in 3 patients, modified (purely in terms of its components) in 17 patients, and increased in 15 patients. Conclusions: Quetiapine was effective in the treatment of hallucinations and delusions in PD. It did not worsen motor functions and allowed the dopaminergic treatment in PD patients affected by MDs to be managed safely.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalClinical Neuropharmacology
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Delusions
Hallucinations
Parkinson Disease
Mental Disorders
Therapeutics
Dopamine Agents
Quetiapine Fumarate
Cognition
Antipsychotic Agents
Guidelines

Keywords

  • Delusion
  • Hallucination
  • Parkinson disease
  • Quetiapine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. / Mancini, Francesca; Tassorelli, Cristina; Martignoni, Emilia; Moglia, Arrigo; Nappi, Giuseppe; Cristina, Silvano; Pacchetti, Claudio.

In: Clinical Neuropharmacology, Vol. 27, No. 1, 01.2004, p. 33-37.

Research output: Contribution to journalArticle

Mancini, Francesca ; Tassorelli, Cristina ; Martignoni, Emilia ; Moglia, Arrigo ; Nappi, Giuseppe ; Cristina, Silvano ; Pacchetti, Claudio. / Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease. In: Clinical Neuropharmacology. 2004 ; Vol. 27, No. 1. pp. 33-37.
@article{01ea312dc1bf482da3042a93df7c96bf,
title = "Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease",
abstract = "Objectives: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out to demonstrate the short- and long-term efficacy of quetiapine, an antipsychotic drug, in controlling hallucinations and delusions in parkinsonian patients without worsening their motor function. Since current guidelines recommend that dopaminergic drugs be decreased or even withdrawn altogether upon the appearance of MDs, we also sought to establish whether quetiapine enables a modification of this common course of action, and hence improve the management of pre-existing motor complications in affected subjects. Method: Thirty-five PD patients with disabling MDs were enrolled in this open-label study. Motor function, MDs and cognitive state were evaluated before starting quetiapine therapy and after 1, 3, and 12 months of treatment. Results: MDs significantly improved after 1, 3, and 12 months of quetiapine treatment. At the end of the study the mean daily dose of quetiapine (185 mg) did not produce significant changes in motor or cognitive function. Isolated hallucinations responded to low doses of quetiapine (110 mg daily), while delusions needed 265 mg daily. After 12 months, global dopaminergic therapy was reduced in 3 patients, modified (purely in terms of its components) in 17 patients, and increased in 15 patients. Conclusions: Quetiapine was effective in the treatment of hallucinations and delusions in PD. It did not worsen motor functions and allowed the dopaminergic treatment in PD patients affected by MDs to be managed safely.",
keywords = "Delusion, Hallucination, Parkinson disease, Quetiapine",
author = "Francesca Mancini and Cristina Tassorelli and Emilia Martignoni and Arrigo Moglia and Giuseppe Nappi and Silvano Cristina and Claudio Pacchetti",
year = "2004",
month = "1",
doi = "10.1097/00002826-200401000-00010",
language = "English",
volume = "27",
pages = "33--37",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Long-Term Evaluation of the Effect of Quetiapine on Hallucinations, Delusions and Motor Function in Advanced Parkinson Disease

AU - Mancini, Francesca

AU - Tassorelli, Cristina

AU - Martignoni, Emilia

AU - Moglia, Arrigo

AU - Nappi, Giuseppe

AU - Cristina, Silvano

AU - Pacchetti, Claudio

PY - 2004/1

Y1 - 2004/1

N2 - Objectives: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out to demonstrate the short- and long-term efficacy of quetiapine, an antipsychotic drug, in controlling hallucinations and delusions in parkinsonian patients without worsening their motor function. Since current guidelines recommend that dopaminergic drugs be decreased or even withdrawn altogether upon the appearance of MDs, we also sought to establish whether quetiapine enables a modification of this common course of action, and hence improve the management of pre-existing motor complications in affected subjects. Method: Thirty-five PD patients with disabling MDs were enrolled in this open-label study. Motor function, MDs and cognitive state were evaluated before starting quetiapine therapy and after 1, 3, and 12 months of treatment. Results: MDs significantly improved after 1, 3, and 12 months of quetiapine treatment. At the end of the study the mean daily dose of quetiapine (185 mg) did not produce significant changes in motor or cognitive function. Isolated hallucinations responded to low doses of quetiapine (110 mg daily), while delusions needed 265 mg daily. After 12 months, global dopaminergic therapy was reduced in 3 patients, modified (purely in terms of its components) in 17 patients, and increased in 15 patients. Conclusions: Quetiapine was effective in the treatment of hallucinations and delusions in PD. It did not worsen motor functions and allowed the dopaminergic treatment in PD patients affected by MDs to be managed safely.

AB - Objectives: Mental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out to demonstrate the short- and long-term efficacy of quetiapine, an antipsychotic drug, in controlling hallucinations and delusions in parkinsonian patients without worsening their motor function. Since current guidelines recommend that dopaminergic drugs be decreased or even withdrawn altogether upon the appearance of MDs, we also sought to establish whether quetiapine enables a modification of this common course of action, and hence improve the management of pre-existing motor complications in affected subjects. Method: Thirty-five PD patients with disabling MDs were enrolled in this open-label study. Motor function, MDs and cognitive state were evaluated before starting quetiapine therapy and after 1, 3, and 12 months of treatment. Results: MDs significantly improved after 1, 3, and 12 months of quetiapine treatment. At the end of the study the mean daily dose of quetiapine (185 mg) did not produce significant changes in motor or cognitive function. Isolated hallucinations responded to low doses of quetiapine (110 mg daily), while delusions needed 265 mg daily. After 12 months, global dopaminergic therapy was reduced in 3 patients, modified (purely in terms of its components) in 17 patients, and increased in 15 patients. Conclusions: Quetiapine was effective in the treatment of hallucinations and delusions in PD. It did not worsen motor functions and allowed the dopaminergic treatment in PD patients affected by MDs to be managed safely.

KW - Delusion

KW - Hallucination

KW - Parkinson disease

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=1442300046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442300046&partnerID=8YFLogxK

U2 - 10.1097/00002826-200401000-00010

DO - 10.1097/00002826-200401000-00010

M3 - Article

VL - 27

SP - 33

EP - 37

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 1

ER -